Breaking News

Industry Lineup Is Set For OTC Hearing

March 24, 2014

Public hearings get underway on March 25.

The OTC Monograph Public Meeting begins tommorrow, March 25,  at the Food and Drug Administration's White Oak campus in Silver Springs, MD. FDA would like input on how to improve the current OTC Monograph Process for reviewing certain nonprescription drugs. The public hearing is being held to obtain information and comments from the public on the strengths and weaknesses of the current OTC Monograph Process, the feasibility of potential modifications the Agency has identified, and ideas about other modifications or alternatives to this process. The meeting continues on March 26.

Here's the lineup of presenters:

March 25, 2014
9:00 am: Janet Woodcock, MD, Director, Center for Drug Evaluation and Research
9:15 am: Robert Guidos, JD, Senior Advisor to the Director, CDER
9:30 am: William Soller, University of California, San Francisco
9:45 am: Scott Melville, David Spangler, Barbara Kochawaski, Consumer Healthcare Products Association
10:15 am: Scott Bass, SidleyAustin, LLP
10:30 am: Break
10:45 am: Lauren Quinn, Novartis Consumer Health Inc.
11:00 am: Greg Collier, Procter and Gamble Company
11:15 am: Elizabeth Anderson, Personal Care Products Council
11:30 am: Lunch
12:30 pm: Leo Beletsky, Northeastern University School of Law & Bouve College of Health
12:45 pm:  Greg O’Neill, The Gerontological Society of America
1:00 pm: Craig Weiss, Independent Cosmetic Manufacturing and Distribution, ICMAD
1:15 pm: Gabrielle Cose, The PEW Charitable Trust
1:30 pm: Jim Czaban, Wiley Rein
1:45 pm: Valerie Ramsey, CB Fleet Company, Inc.
2:00 pm: Break
2:15 pm: Lynne Szczepaniak, Ed Kuffner, McNeil Consumer Healthcare Products
2:35 pm: Kathleen Neville, MD, American Academy of Pediatrics
2:50 pm: Peter Barton Hutt
3:05 pm: Closing Remarks

 
March 26, 2014
9:00 am: Opening Remarks, Robert Guidos
9:15 am: Daniel Hussar, Philadelphia College of Pharmacy
9:30 am: David Steinberg, Steinberg and Associates
9:45 am: Richard Kingham, Covington and Burling, LLP
10:00 am: Ann Begley, Morgan, Lewis, Brockius
10:15 am: David Schoneker, IPEC Americas
10:30 am: Closing Remarks.


FDA Panel
Presiding Officer: Robert Guidos, JD
Panelists:
• Carol Bennett, JD, Acting Director, Office of Compliance, CDER
• Thomas J. Cosgrove, JD, Director, Office of Unapproved Drugs and Labeling Compliance, Office of Compliance, CDER
• Peter Diak, PharmD, MPH, Team Leader, Division of Pharmacovigilance II, Office of Surveillance and Epidemiology, CDER
• Leslie Kux, JD, Assistant Commissioner for Policy, Office of Policy, Planning and Legislation, Office of the Commissioner
• Theresa M. Michele, MD, Director, Division of Nonprescription Clinical Evaluation, CDER


 

Related End-User Markets:

  • Discourse on Disclosure

    Discourse on Disclosure

    Tom Branna, Editorial Director||January 6, 2017
    Transparency impacts the cleaning industry.

  • The Top Stories of 2016

    The Top Stories of 2016

    December 26, 2016
    The companies and topics that grabbed headlines and your attention this year.

  • Patent Activity: Colgate-Palmolive

    Patent Activity: Colgate-Palmolive

    December 6, 2016
    New oral care compositions, the use of radish root ferment filtrate in a cleanser and more.

  • On the Edge

    On the Edge

    January 6, 2017
    Expanding beauty brands to watch in 2017

  • The World Comes to Orlando

    The World Comes to Orlando

    Tom Branna, Editorial Director||December 1, 2016
    More than 1,600 chemists traveled to Florida for the IFSCC Congress

  • Aromas Revealed: Fragrance Disclosure

    Aromas Revealed: Fragrance Disclosure

    Daniel Greenberg, Agilex Fragrances||November 2, 2016
    Fragrance disclosure is a potentially dangerous issue.